Editas Medicine, Inc. (EDIT)
| Chiusura precedente | 9,98 |
| Aperto | 9,91 |
| Denaro | 9,80 x 900 |
| Lettera | 9,83 x 1000 |
| Min-Max giorno | 9,78 - 10,05 |
| Intervallo di 52 settimane | 9,23 - 31,84 |
| Volume | |
| Media Volume | 1.694.734 |
| Capitalizzazione | 673,877M |
| Beta (5 anni mensile) | 1,88 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,73 |
| Prossima data utili | 22 feb 2023 - 27 feb 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 16,73 |
- GlobeNewswire
Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease
EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant Both patients treated with EDIT-301 successfully engrafted and are free of vaso-occlusive events during the follow-up period First patient treated has a total hemoglobin level of 16.4 g/dL and 45.4% fetal hemoglobin five months after treatment with EDIT-301 Company to host a webinar today at 8:00 a.m. ET CAMBRIDGE, Mass., Dec. 06
- GlobeNewswire
Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on, Tuesday, December 6, at 8:00 a.m. ET to present initial clinical data from the Phase 1/2 RUBY trial of EDIT-301, under development for the treatment of severe sickle cell disease. The clinical data will include safety data from the first two patients and efficacy data from the first patient treated with EDIT-301. T
- GlobeNewswire
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals of consistent improvement in BCVA plus additional efficacy endpoints seen in homozygous patients Achieved proof of concept and identified a responder population In view of the small population, the Company will pause enrollment in the BRILLIANCE trial and seek to identify a collaboration partner to continue development of EDIT-101 Company to host a webinar today at 8:00 a.m. ET CAMBRIDGE, Mass.,
